id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-300236-mon1loph	Williams, Bryan	Hypertension, renin–angiotensin–aldosterone system inhibition, and COVID-19	2020-05-14		.txt	text/plain	1239	50	35	Two factors have contributed to this: first, the observation that hypertension is one of the most common comorbidities associated with severe cases of COVID-19 in patients who have been admitted to hospital and their risk of death; 1 and second, that like the severe acute respiratory syndrome coronavirus (SARS-CoV), SARS-CoV-2 infects cells via specific binding to angiotensin-converting enzyme 2 (ACE2), which is ubiquitously expressed in the lung and other tissues. Thus, an interesting and potentially clinically important finding in the study by de Abajo and colleagues is that the use of RAAS inhibitors compared with other antihypertensive drugs almost halved the risk of adverse outcomes in patients with COVID-19 who had diabetes (adjusted OR 0·53, 95% CI 0·34-0·80). Nor does evidence exist to suggest that, once infected, the risk of admission to hospital due to COVID-19, progression to more severe complications, or death is increased with RAAS inhibitor use compared with treatment with other antihypertensive drugs.	./cache/cord-300236-mon1loph.txt	./txt/cord-300236-mon1loph.txt